97 related articles for article (PubMed ID: 16969902)
1. [Surprisingly positive effect of palliative CAP chemotherapy of bone-disseminated, undifferentiated carcinoma of unknown primary origin in patient with low performance status according to WHO].
Swiatoniowski G; Bruzewicz S; Suder E; Warszylewicz-Szymanek M; Kłaniewski T; Prudlak E; Molenda W; Setta M
Przegl Lek; 2006; 63(3):166-8. PubMed ID: 16969902
[TBL] [Abstract][Full Text] [Related]
2. Long-term remission in a patient with carcinoma of unknown primary site.
Jentsch-Ullrich K; Kalinski T; Roessner A; Franke A; Mohren M
Chemotherapy; 2006; 52(1):12-5. PubMed ID: 16340191
[TBL] [Abstract][Full Text] [Related]
3. Randomized phase III trial of pelvic radiotherapy versus cisplatin-based combined chemotherapy in patients with intermediate- and high-risk endometrial cancer: a Japanese Gynecologic Oncology Group study.
Susumu N; Sagae S; Udagawa Y; Niwa K; Kuramoto H; Satoh S; Kudo R;
Gynecol Oncol; 2008 Jan; 108(1):226-33. PubMed ID: 17996926
[TBL] [Abstract][Full Text] [Related]
4. [Metastatic carcinoma of unknown origin].
Fizazi K; Culine S
Bull Cancer; 1998 Jul; 85(7):609-17. PubMed ID: 9752267
[TBL] [Abstract][Full Text] [Related]
5. Prognostic factors in limited-stage small cell lung cancer of patients treated with combined modality approach.
Cetingöz R; Cetinayak HO; Sen RC; Demiral AN; Akkoçlu A; Osma E; Kargi A; Oztop I; Onen A; Kinay M;
J BUON; 2006; 11(1):31-7. PubMed ID: 17318949
[TBL] [Abstract][Full Text] [Related]
6. [Severe microangiopathic hemolytic anemia as first manifestation of a CUP syndrome. Rapid hematologic remission under polychemotherapy].
Abdel Samie A; Sandritter B; Theilmann L
Med Klin (Munich); 2004 Mar; 99(3):148-53. PubMed ID: 15024487
[TBL] [Abstract][Full Text] [Related]
7. Prognostic significance of adjuvant cisplatin-based combination chemotherapy following radical cystectomy in patients with invasive bladder cancer.
Muramaki M; Miyake H; Kurahashi T; Takenaka A; Inoue TA; Fujisawa M
Int J Urol; 2008 Apr; 15(4):314-8. PubMed ID: 18380818
[TBL] [Abstract][Full Text] [Related]
8. Performance status and cytoreductive nephrectomy: redefining management in patients with poor performance.
Shuch B; La Rochelle JC; Wu J; Klatte T; Riggs SB; Kabbinavar F; Belldegrun AS; Pantuck AJ
Cancer; 2008 Sep; 113(6):1324-31. PubMed ID: 18661529
[TBL] [Abstract][Full Text] [Related]
9. Predictive factors for response and prognostic factors for long-term survival in consecutive, single institution patients with locally advanced and/or metastatic transitional cell carcinoma following cisplatin-based chemotherapy.
Jessen C; Agerbaek M; Von Der Maase H
Acta Oncol; 2009; 48(3):411-7. PubMed ID: 18798018
[TBL] [Abstract][Full Text] [Related]
10. Therapy of stage IV B anaplastic thyroid carcinoma: single institution experience.
Vrbic S; Pejcic I; Vrbic M; Filipovic S
J BUON; 2009; 14(1):41-4. PubMed ID: 19373945
[TBL] [Abstract][Full Text] [Related]
11. Induction chemotherapy with S-1 plus cisplatin in patients with locally advanced squamous cell carcinoma of the head and neck.
Choi YJ; Chung JS; Shin HJ; Cho GJ; Wang SG; Lee BJ; Cho BM; Joo YD; Sohn CH
J Laryngol Otol; 2008 Aug; 122(8):848-53. PubMed ID: 18047761
[TBL] [Abstract][Full Text] [Related]
12. [A case of multiple bone metastases from gastric cancer treated with combination chemotherapy of S-1 and CDDP].
Migita K; Watanabe A; Sakamoto C; Nakamura T; Ohyama T; Ishikawa H; Yamamoto K
Gan To Kagaku Ryoho; 2007 Jun; 34(6):929-31. PubMed ID: 17565259
[TBL] [Abstract][Full Text] [Related]
13. Split course hyperfractionated accelerated radio-chemotherapy (SCHARC) for patients with advanced head and neck cancer: influence of protocol deviations and hemoglobin on overall survival, a retrospective analysis.
Stadler P; Putnik K; Kreimeyer T; Sprague LD; Koelbl O; Schäfer C
BMC Cancer; 2006 Dec; 6():279. PubMed ID: 17150114
[TBL] [Abstract][Full Text] [Related]
14. Response of carcinoma of unknown primary site affecting bone to thalidomide.
Frank RC; Kaplan F; Nair S
Lancet Oncol; 2005 Jul; 6(7):534-5. PubMed ID: 15992704
[No Abstract] [Full Text] [Related]
15. [Cytostatic treatment of metastatic adenocarcinoma and anaplastic carcinoma of unknown primary origin].
Aabo K; Rørth M; Hansen HH
Ugeskr Laeger; 1987 Jan; 149(2):80-1. PubMed ID: 3810973
[No Abstract] [Full Text] [Related]
16. [Prognosis and treatment strategies of primary B-cell and NK/T-cell nasopharyngeal non-Hodgkin's lymphoma at early stage].
Zou GR; Zhang YJ; Xie FY; Zheng W; Li HX; Xia YF; Lin TY; Lu TX
Ai Zheng; 2006 Dec; 25(12):1543-9. PubMed ID: 17166383
[TBL] [Abstract][Full Text] [Related]
17. Identifying patients at high risk for neutropenic complications during chemotherapy for metastatic breast cancer with doxorubicin or pegylated liposomal doxorubicin: the development of a prediction model.
Dranitsaris G; Rayson D; Vincent M; Chang J; Gelmon K; Sandor D; Reardon G
Am J Clin Oncol; 2008 Aug; 31(4):369-74. PubMed ID: 18845996
[TBL] [Abstract][Full Text] [Related]
18. Randomized trial comparing bleomycin/etoposide/cisplatin with alternating cisplatin/cyclophosphamide/doxorubicin and vinblastine/bleomycin regimens of chemotherapy for patients with intermediate- and poor-risk metastatic nonseminomatous germ cell tumors: Genito-Urinary Group of the French Federation of Cancer Centers Trial T93MP.
Culine S; Kramar A; Théodore C; Geoffrois L; Chevreau C; Biron P; Nguyen BB; Héron JF; Kerbrat P; Caty A; Delva R; Fargeot P; Fizazi K; Bouzy J; Droz JP;
J Clin Oncol; 2008 Jan; 26(3):421-7. PubMed ID: 18202419
[TBL] [Abstract][Full Text] [Related]
19. Influence of platinum-based chemotherapy on disseminated tumor cells in blood and bone marrow of patients with ovarian cancer.
Wimberger P; Heubner M; Otterbach F; Fehm T; Kimmig R; Kasimir-Bauer S
Gynecol Oncol; 2007 Nov; 107(2):331-8. PubMed ID: 17764727
[TBL] [Abstract][Full Text] [Related]
20. A phase II study of uracil-tegafur plus doxorubicin and prognostic factors in patients with unresectable biliary tract cancer.
Furuse J; Okusaka T; Ohkawa S; Nagase M; Funakoshi A; Boku N; Yamao K; Yamaguchi T; Sato T
Cancer Chemother Pharmacol; 2009 Dec; 65(1):113-20. PubMed ID: 19404641
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
